Shijiazhuang Pharmaceutical And Unigene Laboratories To Jointly Produce Osteoporosis Drug
This article was originally published in PharmAsia News
Executive Summary
Shijiazhuang Pharmaceutical recently signed an agreement with U.S.-based Unigene Laboratories to co-invest $15 million in a firm to produce the anti-osteoporosis product Salmon Calcitonin. When in operation, the joint venture will produce 70 million Calcitonin injections and 4 million bottles of nasal spray, with an expected 708 million yuan in sales and $51.2 million in foreign exchange per year. In addition, an R&D platform for manufacturing biologics will be set up to develop and commercialize biotech drugs for an international market. (Click here for more)
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.